Nuveen Asset Management, LLC Kronos Bio, Inc. Transaction History

Nuveen Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.34 - $2.62 $14,100 - $27,570	10,523 Added 5.2%	212,946 $310,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $26,814 - $64,056	-18,621 Reduced 8.42%	202,423 $328,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $28,016 - $46,414	-8,363 Reduced 3.65%	221,044 $740,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $196,759 - $474,241	63,064 Added 37.91%	229,407 $835,000
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $117,569 - $270,822	-18,781 Reduced 10.15%	166,343 $1.31 Million
Q4 2021 Feb 14, 2022	BUY	$11.35 - $21.18 $32,733 - $61,083	2,884 Added 1.58%	185,124 $2.52 Million
Q3 2021 Nov 12, 2021	BUY	$18.17 - $24.7 $369,305 - $502,027	20,325 Added 12.55%	182,240 $3.82 Million
Q2 2021 Aug 16, 2021	BUY	$20.08 - $29.02 $2.18 Million - $3.15 Million	108,487 Added 203.05%	161,915 $3.88 Million
Q1 2021 May 17, 2021	BUY	$27.0 - $32.48 $3,591 - $4,319	133 Added 0.25%	53,428 $1.56 Million
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $1.42 Million - $2.04 Million	53,295 New	53,295 $1.59 Million

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $48.8M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.